ADVERTISEMENT
Image of a white cardboard box with a blue vertical stripe on the left side, the word “Apixaban” in blue lettering at the bottom, and a depiction of apixaban’s molecular structure in black.
Blood Thinner Ineffective for COVID-19 Patients: Study
A clinical trial finds that the anticoagulant apixaban, which has been prescribed to help COVID-19 patients recover, is ineffective and in rare instances dangerous.
Blood Thinner Ineffective for COVID-19 Patients: Study
Blood Thinner Ineffective for COVID-19 Patients: Study

A clinical trial finds that the anticoagulant apixaban, which has been prescribed to help COVID-19 patients recover, is ineffective and in rare instances dangerous.

A clinical trial finds that the anticoagulant apixaban, which has been prescribed to help COVID-19 patients recover, is ineffective and in rare instances dangerous.

  1. Home
  2. Subjects
  3. immunology, clinical trials, infectious disease

immunology, clinical trials, infectious disease

A person in a white shirt activates a nasal spray
Oxford-AstraZeneca Nasal COVID-19 Vaccine Falters in Clinical Trial
Dan Robitzski | Oct 11, 2022 | 2 min read
Researchers say they’re abandoning the project in its current form—one of several that aims to induce what’s known as mucosal immunity against SARS-CoV-2.
Antiviral Immunotherapy Comes of Age
Lucas Laursen | Dec 4, 2017 | 5 min read
T-cell therapies are not just for cancer. Researchers are also advancing immunotherapy methods to protect bone marrow transplant patients from viral infections. 
The Year in Pathogens
Molly Sharlach | Dec 28, 2014 | 4 min read
Ebola, MERS, and enterovirus D68; polio eradication efforts; new regulations on potentially dangerous research
Why the Thai HIV Vax Trial Worked
Bob Grant | Sep 19, 2011 | 1 min read
New molecular analyses yield clues to the success of a 2009 human HIV vaccine study.
ADVERTISEMENT
ADVERTISEMENT